BIOAFFINITY TECHNOLOGIES INC

BIAF represents the publicly traded equity of BioAffinity Technologies, a company focused on developing non-invasive diagnostic tests for early-stage lung cancer and other diseases. The stock trades on the Nasdaq Capital Market under the ticker BIAF. As a small-cap healthcare company, its shares are tied to the progress of its proprietary CyPath Lung test and related research programs. BIAF does not pay a regular dividend, and its market activity often reflects investor sentiment around clinical milestones and commercialization efforts.

BIAF operates in the biotechnology and diagnostics sector, specifically within life sciences tools and cancer diagnostics. The company develops technology that uses flow cytometry and machine learning to analyze sputum samples for early detection of lung cancer. This places BIAF in the broader healthcare industry, where companies are subject to regulatory oversight from agencies such as the FDA. Industry factors like clinical trial outcomes, reimbursement decisions, and competition from other diagnostic platforms can influence how the market views BIAF.

Recent performance for BIAF can vary based on company announcements, quarterly filings, and broader market conditions for small-cap biotech stocks. Since BIAF is a lower-volume Nasdaq listing, its share price may experience sharper moves than larger, more established healthcare companies. For the latest price changes, recent trading range, and volume data, check the current BIAF quote and performance section on this page, which reflects real-time or delayed market information.

Evaluating BIAF's valuation is challenging because the company may not yet generate consistent profits, making traditional metrics like the P/E ratio less meaningful. Investors often look at price-to-sales, cash burn rate, and pipeline progress instead. Comparing BIAF to similar diagnostic or early-stage biotech companies can provide context, but each firm's technology, cash position, and regulatory path differ. The most current valuation figures for BIAF are available in the financial highlights or valuation section on this page.

To buy BIAF stock, you generally need a brokerage account that offers access to Nasdaq-listed securities. Once the account is funded, you can place a market or limit order for BIAF shares during regular trading hours. Some brokers also allow extended-hours trading, though liquidity may be thinner. Before trading, confirm any commission fees, minimum order requirements, and whether fractional shares are supported. The exact process depends on your broker, but the ticker BIAF is used across major U.S. brokerage platforms.

BIAF faces several risks common to early-stage diagnostics companies, including clinical trial setbacks, regulatory delays, and the need for additional capital to fund operations. Because it is a small-cap stock, BIAF may have lower trading volume and higher price volatility than larger healthcare peers. Competition from other lung cancer screening methods and the challenge of gaining reimbursement from insurers are also significant. Investors should review BIAF's risk factors in its SEC filings for a complete picture of company-specific uncertainties.